Valuation: Edesa Biotech, Inc.

Market Cap 6.41Cr 5.61Cr 5.17Cr 4.79Cr 9.1Cr 608.47Cr 9.24Cr 62Cr 24Cr 300.29Cr 24Cr 24Cr 1.04TCr P/E 2026 *
-4.34x
P/E 2027 * -3.59x
Enterprise Value 6.41Cr 5.61Cr 5.17Cr 4.79Cr 9.1Cr 608.47Cr 9.24Cr 62Cr 24Cr 300.29Cr 24Cr 24Cr 1.04TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
79.78%
Yield 2026 *
-
Yield 2027 * -
1 day+3.74%
1 week-8.24%
Current month-8.24%
1 month+38.92%
3 months+23.31%
6 months+384.42%
Current year+425.35%
1 week 7.01
Extreme 7.01
8
1 month 4.56
Extreme 4.56
8.89
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2015
Director of Finance/CFO 57 01/05/2025
President 48 07/06/2019
Director TitleAgeSince
Chairman 50 07/06/2019
Director/Board Member 55 07/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap.
02/07Free

Founder

3,378 0.0380%
16/06Free

Founder

1,53,550 1.7268%
16/06Sell

Founder

1,53,530 1.7266%
Change 5-day change 1-year change 3-year change Capi.($)
+3.74%-8.24%+262.14%+26.87% 6.41Cr
-0.10%+0.10%+74.33%+133.26% 5.77TCr
-3.80%-6.24%+67.04%+86.36% 5.47TCr
+0.83%+1.63%-14.07%-11.50% 2.38TCr
+1.90%+6.12%+16.70%+469.71% 2.42TCr
-2.70%+4.25%+40.38%-3.72% 1.98TCr
+3.78%+5.65%+44.99%-26.23% 1.71TCr
+3.46%+17.72%+206.66%+364.07% 1.68TCr
-1.81%+18.00%+41.99% - 1.56TCr
+3.51%+5.40%+29.87%+197.00% 1.4TCr
Average +0.89%+4.40%+77.00%+137.31% 2.44TCr
Weighted average by Cap. -0.23%+3.33%+58.07%+139.54%

Financials

2026 *2027 *
Net sales - -
Net income -1.45Cr -1.27Cr -1.17Cr -1.09Cr -2.06Cr -137.96Cr -2.1Cr -14Cr -5.47Cr -68Cr -5.46Cr -5.34Cr -235.34Cr -2.65Cr -2.32Cr -2.14Cr -1.98Cr -3.76Cr -251.63Cr -3.82Cr -26Cr -9.97Cr -124.18Cr -9.95Cr -9.74Cr -429.23Cr
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
17
Date Price Change Volume
07/26/07 $7.460 +3.47% 49,854
06/26/06 $7.210 -3.87% 65,719
02/26/02 $7.500 -3.23% 68,266
01/26/01 $7.750 -4.67% 46,915
30/26/30 $8.130 +6.00% 1,92,344
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.210USD
Average target price
16.33USD
Spread / Average Target
+126.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock